These data demonstrated a 3.8‐fold reduction of G0S2 expression in CD34+ cells from newly diagnosed CP‐CML patients compared with normal CB, with further downregulation by 3.1‐fold in myeloid BP‐CML (Figure 1A). The gene discussed is G0S2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.